Business Wire

HENLEY-&-PARTNERS

28.10.2020 12:30:10 CET | Business Wire | Press release

Share
Australia’s Global Talent Visa Program Sees Tech CEOs Swap Silicon Valley for Sydney

Australia’s Global Talent Visa Program, also known as the Global Talent Independent Program, is making waves across the Pacific, attracting dynamic, high-profile business leaders to the country’s shores, with many hailing from the US. The program is fine tuned to attract only the world’s premium business talent, and this highly targeted approach has proven to be a great success as clients include top Palo Alto executives and leading Tech CEOs.

The program is aimed at highly skilled individuals and high-income earners and was expressly designed to grow Australia’s innovation and tech economies. The seven future-focused target sectors: AgTech, Space and Advanced Manufacturing, FinTech, Energy and Mining Technology, MedTech, Cyber Security, and Quantum Information, Advanced Digital, Data Science and ICT. With no age limit or investment prerequisite, the only requirements for applicants are to be internationally recognized, prominent in their field, and able to provide evidence of outstanding achievements. There are 15,000 places available in 2020–2021, and successful applicants can obtain fast-tracked permanent residence for the whole family within six weeks and have a full five years to make the move Down Under. Places are also available to internationally recognized master’s and PhD students who can demonstrate their exceptional talent.

Director of leading international citizenship and residence advisory firm Henley & Partners’ Australia office, Tony Le Nevez , says the country’s prosperity, safety, and excellent quality of life make it a highly sought-after destination for high-net-worth individuals and entrepreneurs. “Stimulating innovation — and tech innovation in particular — should be a non-negotiable for any sovereign state in the current context. By attracting and harnessing the world’s cutting-edge talent, Australia’s permanent residence offering will ensure that the country stays well ahead of the game. The coronavirus-related events of 2020 have provoked a desire for change, leading many individuals to seek out alternative options. We have seen a huge spike globally in interest in investment migration programs, and from Americans in particular. The Global Talent Visa Program presents a perfect opportunity for matching top global talent with a safe, reliable, and successful country that is forward looking.”

Dominic Volek , Henley & Partners Group Head of Private Clients, says “Contrary to what many believe, residence and citizenship programs are not the exclusive domain of nations that are struggling economically or starved of foreign capital. Nineteen of the Group of 20 nations, including the UK and the US, offer a mechanism to attract inward investment in exchange for residence rights. Sixty percent of EU member states offer investment migration programs. These highly developed nations design and implement these programs for the same reasons small and developing nations do — to attract foreign capital, skills, and knowledge to stimulate their domestic economies.”

For successful HNWI who might not be the next Steve Jobs, Australia offers various pathways to permanent residence. Under the Skilled – Investment/Entrepreneurial program there are six main streams for business innovators, investors, significant investors, entrepreneurs, business talent, and venture capitalist entrepreneurs, with minimum requirements ranging from business turnover of AUD 500,000 and net assets of AUD 800,000 (Business Innovation stream) to committing at least AUD 5 million into a complying Australian investment for at least four years (Significant Investor stream). If Australia appeals, it is advisable to apply in the next six to eight months, as significant changes are on the horizon with an announcement expected in July 2021.

Social Media:

https://www.facebook.com/HenleyPartners/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Vertex to Acquire Crinetics Pharmaceuticals6.7.2026 22:04:00 CEST | Press release

- Crinetics adds potential best-in-class commercialized and Phase 3 endocrinology assets with ~$5 billion peak sales opportunity to Vertex’s portfolio - - PALSONIFY®, Crinetics’ recently launched, first and only, once-daily oral therapy for adults with acromegaly has demonstrated strong and growing early uptake - - Atumelnant, a once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist in Phase 3 development for congenital adrenal hyperplasia (CAH), has shown unique and transformative potential to both normalize androgen levels and enable management of patients with physiologic levels of glucocorticoids, the true goal of CAH management; atumelnant has also demonstrated therapeutic potential in patients with Cushing’s syndrome - - Acquisition adds to Vertex’s innovation pipeline, accelerates Vertex’s revenue growth and enhances long-term earnings profile - - Vertex to host investor call today, July 6 at 4:30 p.m. ET - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and C

Ciauru Wins the Second Edition of the Reply AI Music Contest, the International Competition Dedicated to Experimentation Across AI, Music and Live Performance6.7.2026 20:30:00 CEST | Press release

The winner was announced on the Kappa FuturFestival stage, following the performances of the five finalists selected by the international jury.German duo PARAFRAME & Avis Vox received the special Reply AI Studios Grand Prix award. The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706007611/en/ The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival First place went to Ciauru, the stag

Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 20266.7.2026 15:00:00 CEST | Press release

Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced it will report earnings after market close on July 30, 2026. The company will host a conference call and webcast on that date to discuss the second quarter 2026 results and the second half 2026 outlook at 5:00 p.m. Eastern / 2:00 p.m. Pacific time. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706560476/en/ Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 2026 A live webcast of the event will be available on Rimini Street’s Investor Relations site via the Rimini Street IR events link and directly via the webcast link. Dial-in participants can access the conference by dialing 1-800-836-8184. A replay of the webcast will be available for one year following the event. About Rimini Street, Inc. Rimini Street, Inc. (Nasda

Orion and Shilpa Medicare Expand Partnership to Develop and Supply Nivolumab Biosimilar for Europe6.7.2026 15:00:00 CEST | Press release

Shilpa Medicare Limited announced that its wholly owned subsidiary, Shilpa Biologicals Private Limited, has entered into a co-development and supply agreement with Orion Corporation for intravenous (IV) nivolumab biosimilar referencing one of the world’s most widely used cancer immunotherapies to widen patient access across Europe. Nivolumab helped usher in the era of immuno-oncology, transforming the outlook for patients with cancers such as melanoma and lung cancer. As the originator approaches loss of exclusivity in Europe, this partnership aims to put a high-quality, EU-GMP-manufactured nivolumab biosimilar within reach of more patients, reducing healthcare burden. In 2025, Nivolumab recorded sales of approximately USD4.1 billion (Source: IQVIA/IMS) Europe — underscoring the scale of the opportunity. Under the agreement, Orion will hold the exclusive rights to register, market, distribute and sell the nivolumab biosimilar across Europe. Shilpa Biologicals will lead product developm

No-Loss Trading Platform UpsideOnly Surpasses 100,000 Users Within Weeks of Launch6.7.2026 14:48:00 CEST | Press release

Rapid growth shows strong demand for a new trading model where users can make market predictions without risking their own capital Perpetuals.com Ltd (Nasdaq: PDC), today announced that UpsideOnly, its risk-free trading and market prediction platform, has seen a surge in new user sign-ups, surpassing the important milestone of 100,000 traders within weeks of its launch on May 19. UpsideOnly lets users make predictions about where global equity, commodity, forex, and crypto markets are heading without ever placing a real trade themselves. Perpetuals uses its own capital to trade on the strongest signals identified by its proprietary AI. If those trades win, Perpetuals shares the profits with the users who helped generate the signal. If the trade doesn’t make money, users lose nothing. Reaching 100,000 users so quickly after launching is a reflection of the enormous demand for a platform that flips the traditional retail trading model on its head, with early platform data showing strong

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye